Trial Profile
Randomized Phase II study of SOX vs mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer (KSCC1301)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 01 Mar 2019 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 Results assessing efficacy and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 29 Mar 2016 Status changed from recruiting to active, no longer recruiting.